Registration Application form for Vaccines (To be submitted in duplicate electronic copies)

Similar documents
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE

MEDICINES CONTROL COUNCIL

Table of Contents Section 1: Section 2: Section 3: Section 4: Section 5: Section 6: Section 7:

GUIDELINE FOR REGISTRATION OF MEDICINES

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country

FOOD AND DRUGS AUTHORITY

Documentation requirements for an initial consultation

Medicines Control Authority of Zimbabwe

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

Vaccine Prequalification Dossier

GUIDELINES FOR MEDICINAL PRODUCT REGISTRATION

Pharmaceutical Regulatory Authority GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET

Registration and renewal of the credential certificate for registration

MEDICINES CONTROL COUNCIL

[Insert name of product/s covered by the protocol]

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS

G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.

WHO PQ dossier Module I. DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane

BIOEQUIVALENCE TRIAL INFORMATION

REPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG

Guidelines for application for Registration of Medicinal Products 2006(DRA)

Vaccine Assessment for Prequalification and Programmatic Suitability for Prequalification

MEDICINES CONTROL COUNCIL

Medicine Variations Guideline

DRUG REGULATORY PROCEDURES IN TANZANIA: A GLIMPSE

Medicines Variations Guideline

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

DRUG DRAFT GUIDELINE FOR REGISTRATION OF MEDICAL DEVICES FOR HUMAN USE IN UGANDA, SEPTEMBER 2009

TABLE OF CONTENTS. 1. Introduction

GUIDELINES FOR REGISTRATION OF MEDICINES IN THE GAMBIA

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

MINISTRY OF PUBLIC HEALTH GENERAL SECRETARIAT MADAGASCAR DRUG S AGENCY EDÑ Ì ÑFG EFÌGD EÌD

Local Pharmaceutical Manufacturer Licensing Procedure

GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS

MINISTRY OF HEALTH AND SOCIAL SERVICES

Medicines Control Authority Of Zimbabwe

APPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT FOR HUMAN USE IN UGANDA

Dossier for marketing authorization in the European Union

Overview of global registration of vaccines

ANMAT Order No 5260/2008

Raw Material and Manufacturer Approval Procedure

INFORMATION REQUIRED FROM PHARMACEUTICAL FIRMS FOR REGISRATION

On the Q&A to the Guideline for Common Technical Documents

Vaccine Assessment for Prequalification and Programmatic Suitability for Prequalification

PAHO HQ Library Cataloguing-in-Publication

WHO guidelines on variations to a prequalified product

5. Changes to a CEP or to a confirmation of API-prequalification document 106

Director of Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare

MEDICINES CONTROL COUNCIL

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL

to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES

GOOD MANUFACTURING PRACTICES - AUDIT REPORT FORM AKA GMP Standards Program

Guidelines on procedures and data requirements for changes to approved biotherapeutic products

Annual Renewal for a Certificate of Authorization for a Health Profession Corporation

GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G

NOTICE TO APPLICANTS. VOLUME 6B Presentation and content of the dossier-part 1 Summary of the dossier Part 1A Application form OCTOBER 2008

APPLICATION FORMS & SUMMARIES TO CONDUCT CLINICAL TRIALS IN TANZANIA

COMMON TECHNICAL REQUIREMENTS ACTR. one vision one identity one community

DRUGS DIRECTORATE GUIDELINES PREPARATION OF DRUG IDENTIFICATION NUMBER SUBMISSIONS

Global Clinical Trial

CMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration

APPLICATION FOR GAS WORK LICENCE (HYDROCARBON REFRIGERANTS)

Investigational New Drug Application

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Pre-qualification of single-use injection devices under the PQS system: A guideline for manufacturers

GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS

Medical Devices. The technical requirements also apply when the submitter is not the legal manufacturer 1 (i.e: a distribution company).

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

Guidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines

WARNING LETTER AUG 3, 2016

ZAMBIA MEDICINES REGULATORY AUTHORITY APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations

Guideline on requirements for the production and control of immunological veterinary medicinal products

GUIDELINE FOR THE STABILITY TESTING

DRUGS CONTROL ORGANISATION

MEDICINES CONTROL COUNCIL

Global Clinical Trial

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

MODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER (QOS PD)

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

APPLICATION FOR VENDOR REGISTRATION Read the instructions and conditions at the end of this application format before preparing to fill-in the form.

GUIDELINES FOR SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF VETERINARY VACCINES IN ZIMBABWE

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

BATCH DISPOSITION BATCH DISPOSITION REGULATION. Jakarta 14 DECEMBER Speaker: MIMI VIRLANY SYAHPUTRI, M.Sc., S.si., APT

DRUG REGISTRATION REGULATION

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations.

Manual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:

Kingdom of Swaziland Ministry of Health. Guidelines on Import Procedures for Medicines

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

Transcription:

Cover letter addressed to: Registration Application form for Vaccines (To be submitted in duplicate electronic copies) THE CHIEF EXECUTIVE FOOD AND DRUGS AUTHORITY P. O. BOX CT 2783 CANTONMENTS-ACCRA GHANA. Note: Samples and electronic documents should be forwarded to the FDA through the local agent; customs duty and clearance are to be effected by the applicant in all instances. SUBMISSION SHOULD ALWAYS BE DONE BY A COMPETENT TECHNICAL OFFICER 1. PRODUCT DETAILS (MUST BE COMPLETED) Full Name of Product (proprietary name): Human or Veterinary (if veterinary, state target species): International Non-Proprietary Name (INN): Is this Vaccine registered in other countries? If yes, list countries and registration numbers: WHO prequalification (PQ) status (please provide PQ date): Pharmacological classification: Pharmaceutical form: Formulation type: Mode of usage: Concentration/Strength: Appearance/Colour: Proposed use: Active constituent(s): Category of distribution: Proposed distribution network: VVM type: Page 1 of 12

Country of origin: Marketing authorization holder: Marketing authorization number & date (country of origin) FOR OFFICIAL USE ONLY Application tracking number: Registration number: First renewal: Second renewal 2. APPLICANT CONTACT INFORMATION (MUST BE COMPLETED) Full name of applicant (must be a company): Manufacturing company registration certificate number (including accessory companies): Name of contact person(s): Title and / or designation: Street or physical address (applicant): Postal address (applicant): E-mail (applicant): Telephone number(applicant): Fax number(applicant): 3. DECLARATION (MUST BE COMPLETED) Note: Only a body incorporated in Ghana can be appointed as a local agent for this application Full name of local agent (must be a registered company): Registrar general s registration number: Name of Contact person (s): Title and /or designation: Postal address (local agent): Street or physical address (local agent): E-mail (local agent): Telephone number(local agent): Fax number(local agent): Page 2 of 12

Full name of Superintendent Pharmacist: Registration number of Superintendent Pharmacist: Correspondence about this application is to be addressed to: Applicant or local agent I declare that the information provided with this application is complete and correct. Signature (MUST be in ink): Date: Official stamp: False declaration may lead to prosecution. Page 3 of 12

4. PRODUCT DATA Data must be accompanied by a table of content, information shall be provided in soft copy-duplicate (An electronic format saved on a CD). 5. REFERENCE PRODUCT State the rationale for the choice of reference product: Reference product Registration status in Ghana(please indicate as registered or not registered) Specification Distinct Prescribed Uses 6. DISTINCT PRESCRIBED USES List all proposed distinct uses (for veterinary, state target species and situation) 7. FORMULATION DETAILS (MUST BE COMPLETED) Provide the full details below (every constituent must be listed). Provide the full formulation details of the product. For details on required information, refer to Chemistry and Manufacture data (page 14) in the GHFDA Guideline for Registration of Biological Products. Formulation details submitted on this page can only be disclosed to: (select appropriate more than one if applicable) Applicant Manufacturer Approved Person Other Details. Note: Unless indicated on this form or separately in writing, formulation details will not be disclosed to any person other than the provider of the information. Page 4 of 12

TABLE OF FORMULATION DETAILS (a) Name of Biological active constituent Minimum release titre Maximum release titre End of shelf life titre Purpose in formulation (b) Name of Biological active constituent Concentration/ Quantity Specification Purpose in formulation (c) Non-biological active constituent name (if applicable) Concentration/ Quantity Specification Purpose in formulation (d) Other constituents Concentration/ Quantity Specification Purpose in formulation Total weight/weight (solids, semi-solids) or weight/volume (liquids): Specific gravity (SG) (liquids only): Formulation type (eg solution, suspension, lyophilised): Does the product contain ingredients with a risk of transmitting agents of animal spongiform encephalopathy? Does the product contain a genetically-modified organism (GMO) or any product derived from a GMO? For imported ingredients of biological origin, copies of relevant GHFDA import Permit must be attached Does the application submission contain information on the source(s) of raw materials (Biological and nonbiological): Page 5 of 12

Yes No Does the finished formulation contain any ingredient of human origin: Yes No If yes: Provide detailed information on the culturing and techniques, as well as all certificates to demonstrate the virus/pathogen-free status of the ingredient: (Refer to Manufacturing process considerations (section 2.2.2)) I declare that the provided formulation information is complete and correct. Signature (MUST be in ink): Date: False declaration may lead to prosecution. 8. MANUFACTURERS DETAILS (MUST BE COMPLETED) The manufacturer must be licensed to manufacture the product for which this registration application applies. Include the name and street address of all facilities involved in any step of manufacture, including packaging & labelling, contractors and analytical laboratories where applicable. Company name 1. 2. 3. Company s registration number Street/physical address of manufacturing site 4. Provide details of responsible person performing Release for Supply : Name of responsible person: Position: Title: Company name: Street address: E-mail: Telephone number: Fax number: Extent/Stage of manufacture (attach flow diagram) Page 6 of 12

9. EVIDENCE OF GOOD MANUFACTURING PRACTICE (MUST BE COMPLETED) The name and address of the manufacturers shown on the evidence of GMP must correspond with the manufactures detailed under section 8. Indicate the type of evidence provided and submit copies of valid certificates. Manufacturer(s): Evidence of GMP: 1. 2. 3. 1. 2. 3. 10. MANUFACTURER(S) OF ACTIVE CONSTITUENTS (MUST BE COMPLETED) Name and site address of manufacturer Active constituent Reference (EP, BP, USP, IP, other specification) Source/history of culturing and extraction Identity (strain, genus, species and serotype/biotype) Unique identifier/descriptor (gene/phage type, molecular weight extract etc.) Master seed code and passage level Working seed code and passage level 1 st Active constituent 2nd Active constituent (if applicable) Note: If the product contains more than two active constituents, please attach a separate table. 11. CONTAINER AND PACK SIZE DETAILS (MUST BE COMPLETED) Proposed pack size(s) Brief description of the packaging material, including that which is in direct contact with the product (i.e. primary and secondary packaging). Method of label attachment Provide details of product presentation (e.g. single glass bottle inside individual cardboard carton with enclosed leaflet). Page 7 of 12

12. STORAGE STABILITY DETAILS (MUST BE COMPLETED) The proposed shelf life from the date of manufacture. FDA/SMC/BPU/AP-RVC/2016/08 Proposed in-use shelf life: Proposed storage conditions: (e.g. between 2 C and 8 C. Refrigerate. Do not freeze) Submit a comprehensive stability study protocol, data and report on three (3) consecutive batches to support the storage stability of the product. For biological products in multiple dose containers: Submit an in-use stability study to support the in-use shelf life of the product. Submit a detailed storage temperature profile of the product (i.e. transportation and excursions). 13. LABEL DETAILS Pack sizes (in content volume; e.g. ml): Submit four (4) copies of the product label in the appropriate format in accordance with requirements. 14. APPLICANT S CHECKLIST (MUST BE COMPLETED) Tick the appropriate boxes to verify that required documentation is attached: Application Overview completed including outline of exact purpose of application (and all relevant attachments) Appropriate fee Application form signed in ink and completed all relevant sections Completed batch release records, if applicable (Refer to www.fdaghana.gov.gh for minimum batch release requirements for specific products) Page 8 of 12

Application Overview Refer to section 1 of the GHFDA guidelines for registration of biological products when completing this section. The application overview below should not exceed 20 pages. 1. 1.1 Introductory Information (a) Completed application form [The completed application form is all that is required for section 1.1 (a)] (b) Executive summary [Describe the purpose of the application and your reasons for submitting the application. Provide justification for the application] [Briefly summarise the issues associated with the application] (c) Biological properties of the product [Type of immune response and correlation with protection] (d) Reference product (if applicable) [Enter the name and product number of any reference product(s) or write not applicable ] (e) Registration status in other countries [Provide details of any known current or previous applications or approvals in other countries for products containing the same active constituent] (f) Registration status for related formulations [Provide details of any known current or previous applications or approvals in Ghana or other countries for products containing the same active constituent/s in different commercial presentations or different potency ratio] (g) Indicate whether the data presented with this application contradicts or changes the conclusions made from data provided previously Page 9 of 12

1.2 Chemistry and Manufacture [Declare whether section 2 (chemistry and manufacture) has been provided. If not, justify why it is not required] [Briefly (in one paragraph) summarize any stability studies that have been submitted in section 2] [Insert the product s batch release and expiry specifications here] 1.3 Toxicology [Declare whether Section 3 (toxicology) has been provided. If not, justify why it is not required] [Briefly summarize any toxicology studies that have been submitted in Section 3] 1.4 Metabolism & Kinetics [Declare whether a Section 4 (metabolism and kinetics) has been provided. If not, justify why it is not required] [Briefly summarize any metabolism & kinetics data that has been submitted in Section 4] 1.5 Occupational Health and Safety [Declare whether a Section 5 (OH&S) has been provided. If not, justify why it is not required] [Briefly summarize any OH&S data that has been submitted in Section 5] 1.6 Environmental Safety [Declare whether Section 6 (environmental safety) has been provided. If not, justify why it is not required] [Briefly summarize any environmental data that has been submitted in Section 6] 1.7 Safety and Efficacy [Declare whether a Section 7 (safety and efficacy) has been provided. If not, justify why it is not required] Page 10 of 12

[If Section 7 has been provided, insert the summary section of the safety and efficacy studies below] 1.8 Special Data [Declare whether a separate special data dossier(s) (Section 8), relating to genetically-modified organisms, has been provided. If a separate Section 8 has not been provided, justify why it is not required] [Briefly summarize any data on GMOs that has been submitted in Section 8] Page 11 of 12

Attachments Attachments (where applicable) should be indicated in the table of attachments and attached to this Application Form and Overview. Table of attachments Attachment Attached? Product label in appropriate format Product Data GMP certificates/documentation GHFDA import permit Evidence of purchase of reference product (if applicable) Other (specify) Note: The entire application should be submitted with a table of contents. The total number of pages in the application, and total number of pages of attachments and appendices should be clearly stated. Page 12 of 12